LDL: da síndrome metabólica à instabilização da placa aterosclerótica

• Autor(a) principal: Siqueira, Antonela F.a. [UNIFESP]
• Data de Publicação: 2006
• Outros Autores: Abdalla, Dulcineia Saes Parra, Ferreira, Sandra Roberta Gouvea [UNIFESP]
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• dARK ID: ark:/48912/001300000w1hp
• DOI: 10.1590/S0004-27302006000200020
• Texto Completo: http://dx.doi.org/10.1590/S0004-27302006000200020; http://repositorio.unifesp.br/handle/11600/3038
• topic: Low density lipoprotein; Oxidation; Metabolic syndrome; Atherogenesis; Lipoproteína de baixa densidade; Oxidação; Síndrome metabólica; Aterogênese

The dyslipidemia of the metabolic syndrome (MS) confers an elevated cardiovascular risk and is characterized by increased concentrations of triglycerides, decreased HDL-cholesterol and qualitative alterations in LDL which renders it more atherogenic, like the small dense LDL. Modified forms of LDL (mLDL) have been detected in vivo in the plasma and atherosclerotic plaques. A minor fraction of the total LDL has an electronegative charge and is represented by a heterogenic subpopulation of particles [LDL(-)], with higher potential to induce endothelial injury. It could be derived from oxidation, glication or other processes that alter its chemical composition and is increased in diabetic, hypercholesterolemic subjects, and in those with established coronary artery disease. mLDL are internalized by macrophages through scavenger receptors, originating foam cells and inducing an immune-inflammatory reaction. In the atherosclerotic process, the action of mLDL continues until plaque rupture and thrombogenesis, when it promotes apoptosis in endothelial and smooth muscle cells, and activates matrix metalloproteinases, weaken the fibrous cap, and further enhance the inflammatory process that ends in the thrombus formation. Development of new laboratory methods is necessary to enhance the clinical applicability of mLDL and the predictive power of the conventional lipid profile and other cardiovascular risk factors of the MS.